On Nov. 4, 2020, Mateon Therapeutics announced the receipt of approval from Instituto Nacional de Salud (INS), the regulatory agency of Peru, to initiate the Company’s C001- phase 2 clinical trial of OT-101, a TGF-antisense, for treatment of patients with mild to severe COVID-19 infection.

The study planned to enroll 48 patients in Peru totaling 72 patients study wide.